Welcome to our dedicated page for Medpace Holdings SEC filings (Ticker: MEDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medpace Holdings, Inc. filings document formal disclosures for a global clinical contract research organization, including 8-K reports that furnish quarterly and annual financial results. Those reports cover operating measures such as revenue, EBITDA, backlog conversion, net new business awards and book-to-bill ratios for its Phase I-IV clinical development services.
Medpace filings also include proxy materials addressing governance, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document credit-facility amendments involving operating subsidiaries and executive-officer succession matters.
Medpace Holdings, Inc. General Counsel & Corporate Secretary Stephen P. Ewald reported an exercise-and-sell transaction in company stock. He exercised options covering 16,349 shares of common stock at $138.87 per share and sold 16,349 shares in an open-market sale at $450.00 per share pursuant to a limit order placed during an open window period. Following these transactions, he holds 20,343 common shares directly.
Medpace Holdings, Inc. reported results of its 2026 annual stockholder meeting and related governance changes. Stockholders approved amendments to the Restated Certificate of Incorporation to remove supermajority voting requirements and to remove the prior limitation on stockholders calling special meetings, effective upon Delaware filing on May 18, 2026. The Board also amended the bylaws so one or more stockholders owning at least 25% of the Company’s voting power, and having held it continuously for one year, may request a special meeting, subject to notice and information requirements. Stockholders elected all director nominees, ratified Deloitte & Touche LLP as auditor for the year ending December 31, 2026, approved the advisory vote on executive compensation, and supported holding this advisory vote every year.
Medpace Holdings director Dani S. Zander received a stock option grant covering 1,110 shares of common stock at an exercise price of $415.27 per share. This is a compensation-related award, not an open-market trade, and represents a new derivative position for the director.
The option expires on May 15, 2033 and vests on the earlier of the day immediately before the first annual shareholder meeting following the grant date or the first anniversary of the grant date, as long as Zander continues serving on Medpace’s board through that vesting date.
Medpace Holdings, Inc. director Cornelius P. McCarthy III received a grant of stock options covering 1,110 shares of common stock at an exercise price of $415.2700 per share. These options expire on May 15, 2033 and are a compensation-related award, not an open-market purchase.
According to the footnote, the option vests on the earlier of the day immediately preceding the first annual shareholder meeting after the grant date or the first anniversary of the grant, subject to his continued service on the board. Following the reported transactions, he holds 10,324 shares of common stock directly.
Medpace Holdings, Inc. director Robert O. Kraft reported a new stock option award and his current share holdings. He received options to buy 1,110 shares of common stock at an exercise price of $415.27 per share, expiring on May 15, 2033. Following the award, he holds 922 shares of common stock directly. The option vests on the earlier of the day immediately before the first annual meeting after the grant date or the first anniversary of the grant date, subject to his continued service on the board.
Medpace Holdings, Inc. director Femida H. Gwadry-Sridhar received a grant of stock options covering 1,110 shares of common stock. The options have an exercise price of $415.27 per share and expire on May 15, 2033.
According to the terms, the option vests on the earlier of the day immediately preceding the first annual meeting of shareholders following the grant date, or the first anniversary of the grant date, subject to her continued service on the board of directors through the vesting date. Following this grant, she holds options for 1,110 shares directly.
DAVENPORT FRED B JR reported acquisition or exercise transactions in this Form 4 filing.
Medpace Holdings, Inc. director Fred B. Davenport Jr. received a grant of 1,110 stock options to buy common stock at $415.2700 per share, expiring on May 15, 2033. The options vest on the earlier of the day immediately preceding the first annual meeting following the grant date or the first anniversary of the grant, subject to his continued board service. Following this grant, he holds 3,498 shares directly and 2,000 shares indirectly through a trust.
Medpace Holdings, Inc. director Brian T. Carley reported an equity compensation award and updated holdings. He received a grant of stock options covering 1,110 shares of common stock with an exercise price of $415.27 per share, expiring on May 15, 2033.
The option vests on the earlier of the day immediately before the first Medpace annual meeting after the grant date or the first anniversary of the grant, subject to his continued service on the board. Following the reported transactions, Carley directly holds 32,789 shares of Medpace common stock and 1,110 stock options.
Troendle August J. reported acquisition or exercise transactions in this Form 4 filing.
Medpace Holdings, Inc. CEO August J. Troendle reported new equity awards and updated his holdings. He received 10,000 restricted stock units and 20,000 employee stock options, each tied to Medpace common stock. Both awards vest in full on the second anniversary of the grant date, subject to his continued employment.
Following these updates, Troendle holds 646,184 common shares directly and 4,733,019 common shares indirectly through Medpace Investors, LLC, where he has sole voting and investment control but disclaims beneficial ownership beyond his pecuniary interest.